Drugs / NEGALSTOBART
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05088967 | Dec 2021 | non-small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT05039658 | Sep 2021 → Jul 2022 | diffuse large B-cell lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05026593 | Sep 2021 → Feb 2023 | small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04085185 | Dec 2019 → Dec 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06494943 | Jun 2024 → Dec 2026 expected | head and neck squamous cell carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05572463 | Nov 2022 → Jun 2027 | cutaneous melanoma | Innovent Biologics (Suzhou) Co. Ltd. | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06078657 | Oct 2023 → Oct 2024 | esophageal squamous cell carcinoma | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEGALSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314852 ↗ |
| Known as | BI110 | “BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.” NCT05039658 ↗ |
| Known as | IBI110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05572463 ↗ |
| Action | Inhibit | “Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab” PMID 39736787 ↗ Dec 2024 |
| Modality | Monoclonal antibody | “IBI110 (anti-lymphocyte activation gene 3 \[LAG-3\] monoclonal antibody)” NCT05026593 ↗ |
| Route | Intravenous | “IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle” NCT04085185 ↗ |
| Target | LAG3 | “anti-lymphocyte activation gene-3 (LAG-3) antibody IBI110” PMID 41591537 ↗ Jan 2026 |